CE-355621
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. CE-355621 can effectively bind with human c-Met (KD = 200 pM, IC50 = 466 pM) in A549 cells and cyno c-Met (KD = 610 pM) in cynomolgus kidney cells. CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding. CE-355621 significantly inhibits the growth of tumors dependent on the c-Met/HGF pathway. CE-355621 can be used for research on cancer such as glioblastoma and gastric cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocol
- 순도&문서
- References
-
Help & FAQs
Biological Activity
제품 설명
Species Reactivity
Human
|
c-Met |
In Vitro
CE-355621 (0.01-100 nM, 4 h) can efficiently block the binding of c-Met to HGF and induce c-Met degradation in A549 cells[1].
CE-355621 (0.01 nM-10 nM, 24 h) significantly inhibits c-Met activation in U87MG cells[1].
CE-355621 (0.01-10 μg/mL, 48 h) can induce c-Met degradation in U87MG cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
CE-355621 (400 μg, i.p., on day 7 and 14) significantly inhibits tumor growth in female CD-1 nu/nu mice bearing GTL-16 xenografts[1].
CE-355621 (200 μg, i.p., single dose, on day 7) can effectively inhibit tumor volume growth and uptake of 18F-FDG in female nude (nu/nu) mice bearing U87MG xenografts[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:5×106 U87MG cells injected female CD-1 nu/nu mice[1]
-
Dosage:25, 100 and 200 μg
-
Administration:Intraperitoneal injection (i.p.) on day 0, 2, 3, 6 and 8
-
Result:Significantly delayed tumor growth (up to 22.3 days) and inhibited 80 % of c-Met phosphorylation.
-
Animal Model:1.0-5.0×106 GTL-16 cells injected female CD-1 nu/nu mice[1]
-
Dosage:400 μg
-
Administration:Intraperitoneal injection (i.p.) on day 7 and 14
-
Result:Inhibited tumor growth by 85% and reduced c-Met phosphorylation by 48%.
-
Animal Model:1×106 U87MG cells injected female nude (nu/nu) mice[2]
-
Dosage:200 μg
-
Administration:Intraperitoneal injection (i.p.), single dose on day 7
-
Result:Significantly inhibited tumor volume.
Significantly reduced uptake of 18F-FDG.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
신청
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
N/A
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
순도&문서
References
[1]. Michaud NR, et al. Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621. MAbs. 2012 Nov-Dec;4(6):710-23. [Content Brief]
[2]. Tseng JR, et al. Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET. J Nucl Med. 2008 Jan;49(1):129-134. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CE-355621 Related Classifications
HY-P991565 Related Classifications
Powered by Bioz